{"id":"https://openalex.org/W302056891","doi":null,"title":"Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection.","display_name":"Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection.","alternate_titles":[],"publication_year":2009,"publication_date":"2009-02-01","ids":{"openalex":"https://openalex.org/W302056891","mag":"302056891","pmid":"https://pubmed.ncbi.nlm.nih.gov/19197797"},"language":"en","primary_location":{"id":"mag:302056891","doi":null,"is_oa":false,"landing_page_url":"https://www.researchgate.net/profile/Olga_Klibanov/publication/23984102_Elvitegravir_an_oral_HIV_integrase_inhibitor_for_the_potential_treatment_of_HIV_infection/links/5414fbb40cf2788c4b35ab8a.pdf","pdf_url":null,"source":{"id":"https://openalex.org/S4363607180","display_name":"Current opinion in investigational drugs (London, England : 2000)","issn_l":"1472-4472","issn":["1472-4472"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["jufo-1"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Current opinion in investigational drugs","raw_type":null},"parent_works":[],"lineage":["https://openalex.org/W302056891"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5081291784","display_name":"Olga M. Klibanov","orcid":"https://orcid.org/0000-0002-0191-8265","observed_orcids":["https://orcid.org/0000-0002-0191-8265"]},"institutions":[{"id":"https://openalex.org/I148244530","display_name":"Wingate University","ror":"https://ror.org/01yyxv878","country_code":"US","type":"education","lineage":["https://openalex.org/I148244530"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Olga M Klibanov","raw_affiliation_strings":["Wingate University School of Pharmacy, Wingate, NC 28174-0159, USA. o.klibanov@wingate.edu"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Wingate University School of Pharmacy, Wingate, NC 28174-0159, USA. o.klibanov@wingate.edu","institution_ids":["https://openalex.org/I148244530"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5081291784"],"corresponding_institution_ids":["https://openalex.org/I148244530"],"apc_list":null,"apc_paid":null,"fwci":4.6171,"has_fulltext":false,"cited_by_count":55,"citation_normalized_percentile":{"value":0.94268025,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"10","issue":"2","first_page":"190","last_page":"200"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10082","display_name":"HIV/AIDS Research and Interventions","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/elvitegravir","display_name":"elvitegravir","score":1.0},{"id":"https://openalex.org/keywords/hiv-integrase-inhibitors","display_name":"HIV integrase inhibitors","score":0.921999990940094},{"id":"https://openalex.org/keywords/hiv-1-infection","display_name":"HIV-1 infection","score":0.8169999718666077},{"id":"https://openalex.org/keywords/antiretroviral-drug-resistance","display_name":"antiretroviral resistance","score":0.9160000085830688},{"id":"https://openalex.org/keywords/cyp3a4-metabolism","display_name":"CYP3A4 metabolism","score":0.9020000100135803},{"id":"https://openalex.org/keywords/ritonavir-boosting","display_name":"ritonavir boosting","score":0.824999988079071},{"id":"https://openalex.org/keywords/bioavailability","display_name":"bioavailability","score":0.6899999976158142},{"id":"https://openalex.org/keywords/raltegravir","display_name":"raltegravir","score":0.828000009059906},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.6129999756813049},{"id":"https://openalex.org/keywords/oral-antiretroviral-therapy","display_name":"oral antiretroviral therapy","score":0.7889999747276306}],"concepts":[{"id":"https://openalex.org/C2777068322","wikidata":"https://www.wikidata.org/wiki/Q2740966","display_name":"Elvitegravir","level":5,"score":0.992918074131012},{"id":"https://openalex.org/C2780404665","wikidata":"https://www.wikidata.org/wiki/Q421552","display_name":"Raltegravir","level":5,"score":0.9097042083740234},{"id":"https://openalex.org/C2777302000","wikidata":"https://www.wikidata.org/wiki/Q412251","display_name":"Integrase inhibitor","level":5,"score":0.7506375312805176},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.619125247001648},{"id":"https://openalex.org/C2779298103","wikidata":"https://www.wikidata.org/wiki/Q422618","display_name":"Ritonavir","level":5,"score":0.6070245504379272},{"id":"https://openalex.org/C14430832","wikidata":"https://www.wikidata.org/wiki/Q412550","display_name":"Integrase","level":3,"score":0.5393796563148499},{"id":"https://openalex.org/C2780524789","wikidata":"https://www.wikidata.org/wiki/Q5138908","display_name":"Cobicistat","level":5,"score":0.5050492882728577},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.4757765829563141},{"id":"https://openalex.org/C2779502633","wikidata":"https://www.wikidata.org/wiki/Q937224","display_name":"Dolutegravir","level":5,"score":0.41390693187713623},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4080680310726166},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.33121079206466675},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.2119714617729187},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.2013387680053711},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.18050655722618103},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.06167495250701904}],"mesh":[{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004333","descriptor_name":"Drug Administration Routes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004338","descriptor_name":"Drug Combinations","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004353","descriptor_name":"Drug Evaluation, Preclinical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D015394","descriptor_name":"Molecular Structure","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D019428","descriptor_name":"HIV Integrase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D019428","descriptor_name":"HIV Integrase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D019428","descriptor_name":"HIV Integrase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019438","descriptor_name":"Ritonavir","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"mag:302056891","doi":null,"is_oa":false,"landing_page_url":"https://www.researchgate.net/profile/Olga_Klibanov/publication/23984102_Elvitegravir_an_oral_HIV_integrase_inhibitor_for_the_potential_treatment_of_HIV_infection/links/5414fbb40cf2788c4b35ab8a.pdf","pdf_url":null,"source":{"id":"https://openalex.org/S4363607180","display_name":"Current opinion in investigational drugs (London, England : 2000)","issn_l":"1472-4472","issn":["1472-4472"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["jufo-1"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Current opinion in investigational drugs","raw_type":null},{"id":"pmid:19197797","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19197797","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in investigational drugs (London, England : 2000)","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":6,"referenced_works":["https://openalex.org/W1816280009","https://openalex.org/W1968609133","https://openalex.org/W1994491237","https://openalex.org/W2102696289","https://openalex.org/W2154190260","https://openalex.org/W2171711893"],"related_works":["https://openalex.org/W1982056517","https://openalex.org/W2133594819","https://openalex.org/W2154498922","https://openalex.org/W2014673451","https://openalex.org/W2150306873","https://openalex.org/W2017402153","https://openalex.org/W1968340835","https://openalex.org/W2007825562","https://openalex.org/W2064131094","https://openalex.org/W2037625569"],"abstract_inverted_index":{"The":[0],"treatment":[1],"of":[2,10,19,25,31,35,49,97,126,173,184],"HIV":[3],"is":[4,37,76],"often":[5],"complicated":[6],"by":[7,46],"the":[8,17,32,38,53,95,100,123,171,180],"emergence":[9],"antiretroviral":[11],"(ARV)":[12],"resistance,":[13],"which":[14],"has":[15,136],"prompted":[16],"development":[18],"ARV":[20],"drugs":[21],"with":[22,84,99,118,141,144,163,190],"novel":[23,67],"mechanisms":[24],"action":[26],"and":[27,59,91,113,130,143,182],"resistance":[28,139],"profiles.":[29],"One":[30],"newest":[33],"classes":[34],"ARVs":[36],"integrase":[39,68,146],"inhibitors.":[40],"These":[41],"agents":[42],"inhibit":[43],"viral":[44,50],"replication":[45],"preventing":[47],"integration":[48],"DNA":[51],"into":[52],"host":[54],"cell.":[55],"Japan":[56],"Tobacco":[57],"Inc":[58,62],"Gilead":[60],"Sciences":[61],"are":[63,149],"developing":[64],"elvitegravir,":[65,164],"a":[66,114],"inhibitor":[69,102],"undergoing":[70],"phase":[71,154,175],"III":[72,176],"clinical":[73,131,156],"trials.":[74],"Elvitegravir":[75],"predominantly":[77],"metabolized":[78],"via":[79,89],"cytochrome":[80],"P450":[81],"(CYP)3A4,":[82],"along":[83],"minor":[85],"pathways":[86],"including":[87],"glucuronidation":[88],"UGT1A1/3":[90],"oxidative":[92],"metabolism.":[93],"Consequently,":[94],"coadministration":[96],"elvitegravir":[98,119,135,185],"protease":[101],"ritonavir":[103],"(a":[104],"substantial":[105],"CYP3A4":[106],"inhibitor)":[107],"results":[108],"in":[109,150],"significantly":[110],"enhanced":[111],"bioavailability":[112],"longer":[115],"half-life":[116],"than":[117],"alone,":[120],"allowing":[121],"for":[122],"once-daily":[124],"dosing":[125],"elvitegravir.":[127],"In":[128],"vitro":[129],"data":[132],"suggest":[133],"that":[134,148],"an":[137],"overlapping":[138],"profile":[140],"raltegravir":[142],"other":[145],"inhibitors":[147],"development.":[151],"Data":[152],"from":[153],"I/II":[155],"trials":[157,177],"have":[158],"demonstrated":[159],"excellent":[160],"virological":[161],"responses":[162],"as":[165,167],"well":[166],"minimal":[168],"toxicities.":[169],"At":[170],"time":[172],"publication,":[174],"to":[178],"examine":[179],"efficacy":[181],"toxicity":[183],"were":[186],"enrolling":[187],"patients":[188],"infected":[189],"HIV-1.":[191]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W302056891","counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":8},{"year":2013,"cited_by_count":6},{"year":2012,"cited_by_count":6}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
